Clinical standards for diagnosis, treatment and prevention of post-COVID-19 lung disease

• Autor(a) principal: Visca, D.
• Data de Publicação: 2023
• Outros Autores: Centis, R., Pontali, E., Zampogna, E., Russell, A. M., Migliori, G. B., Andrejak, C., Aro, M., Bayram, H., Berkani, K., Bruchfeld, J., Chakaya, J. M., Chorostowska-Wynimko, J., Crestani, B., Dalcolmo, M. P., D'Ambrosio, L., Dinh-Xuan, A. T., Duong-Quy, S., Fernandes, C., García-García, J. M., de Melo Kawassaki, A., Carrozzi, L., Martinez-Garcia, M. A., Martins, P. Carreiro, Mirsaeidi, M., Mohammad, Y., Naidoo, R. N., Neuparth, N., Sese, L., Silva, D. R., Solovic, I., Sooronbaev, T. M., Spanevello, A., Sverzellati, N., Tanno, L., Tiberi, S., Vasankari, T., Vasarmidi, E., Vitacca, M., Annesi-Maesano, I.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10362/158670
• topic: Medicine(all); SDG 3 - Good Health and Well-being

BACKGROUND: The aim of these clinical standards is to provide guidance on 'best practice' care for the diagnosis, treatment and prevention of post-COVID-19 lung disease.METHODS: A panel of international experts representing scientific societies, associations and groups active in post-COVID-19 lung disease was identified; 45 completed a Delphi process. A 5-point Likert scale indicated level of agreement with the draft standards. The final version was approved by consensus (with 100% agreement).RESULTS: Four clinical standards were agreed for patients with a previous history of COVID-19: Standard 1, Patients with sequelae not explained by an alternative diagnosis should be evaluated for possible post-COVID-19 lung disease; Standard 2, Patients with lung function impairment, reduced exercise tolerance, reduced quality of life (QoL) or other relevant signs or ongoing symptoms ≥4 weeks after the onset of first symptoms should be evaluated for treatment and pulmonary rehabilitation (PR); Standard 3, The PR programme should be based on feasibility, effectiveness and cost-effectiveness criteria, organised according to local health services and tailored to an individual patient's needs; and Standard 4, Each patient undergoing and completing PR should be evaluated to determine its effectiveness and have access to a counselling/health education session.CONCLUSION: This is the first consensus-based set of clinical standards for the diagnosis, treatment and prevention of post-COVID-19 lung disease. Our aim is to improve patient care and QoL by guiding clinicians, programme managers and public health officers in planning and implementing a PR programme to manage post-COVID-19 lung disease.